All In Biotech

Drug Trial Radar · NCT03386513

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

179

Actual

Start

Jan 2, 2018

Primary completion

Oct 2, 2024

Study completion Oct 1, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Myeloproliferative Neoplasm

Interventions

  • IMGN632Drug

    CD123-targeted ADC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) ParticipantsTime frame: Up to approximately 81 months

Locations

18 sites in 4 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center /ID# 275372

    Birmingham, Alabama

  • Banner Md Anderson Cancer Center /ID# 269294

    Gilbert, Arizona

  • City of Hope National Medical Center /ID# 269293

    Duarte, California

  • UCLA - University of California Los Angeles Medical Center /ID# 269066

    Los Angeles, California

  • Moffitt Cancer Center /ID# 269291

    Tampa, Florida

  • Dana-Farber Cancer Institute /ID# 269290

    Boston, Massachusetts

  • Roswell Park Cancer Institute /ID# 269289

    Buffalo, New York

  • Duplicate_Duke University Health System /ID# 275370

    Durham, North Carolina

  • Baylor University Medical Ctr. /ID# 275371

    Dallas, Texas

  • MD Anderson Houston /ID# 269288

    Houston, Texas

  • Fred Hutchinson Cancer Center - Seattle - Fairview Avenue North /ID# 269292

    Seattle, Washington

  • Hopital Saint Antoine /ID# 269298

    Paris, France

  • Institut Paoli-Calmettes /ID# 269299

    Marseille, Bouches-du-Rhone, France

  • Duplicate_CHU de Besancon - Jean Minjoz /ID# 275369

    Besançon, Doubs, France

  • CHU Amiens-Picardie Site Sud /ID# 269068

    Amiens, Somme, France

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 269297

    Meldola, Forlì-Cesena, Italy

  • Istituto Europeo Di Oncologia /ID# 269296

    Milan, Milano, Italy

  • Hospital Universitario y Politecnico La Fe /ID# 269295

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.